Drug Digest: Patient Preference Driving Solid Dosage Trends

Published on: 

Webcasts

Webinar Date/Time: Thu, May 22, 2025 11:00 AM EDT

Explore OSD market trends, key challenges, CDMO strategies for bioavailability, and future advances in drug delivery.

Register Free: https://www.pharmtech.com/pt_w/patient-preference

Event Overview:

Solid dosage drug formulations are becoming increasingly popular among patient populations, but there are challenges for developers. This episode of Drug Digest identifies what those challenges are, what are currently some of the most frequently sought-after expert techniques, how CDMOs can leverage their experience in performing those techniques to improve oral solid dosage bioavailability, and what the future holds in terms of advancements in OSD drug delivery.


Interviews featuring:

  • Adi Kaushal, Director and Technology Head, Bioavailability Enhancement, Lonza

This episode of Drug Digest is sponsored by:

  • Catalent
  • Coating Place
  • Veltek
  • Ligand
  • Adare
  • LGM Pharma
  • Gaylord Chemical Corp

Key Learning Objectives:

  • What the current state of the oral solid dosage market is
  • The main challenges facing OSD drug developers
  • What the emerging expert techniques are for OSD formulations
  • How CDMOs can leverage their expertise in those areas to improve bioavailability

Who Should Attend:

  • Solid dosage drug developers
  • Solid dosage drug manufacturers
  • Formulation scientists
  • Development scientists
  • CDMOs

Speaker:

Adi Kaushal
Director and Technology Head for Bioavailability Enhancement
Lonza

Adi Kaushal is the Director and Technology Head for Bioavailability Enhancement at Lonza Bend. He has been with Lonza since 2010. Adi is responsible for overall BAE technology strategy and progression of customer programs from feasibility to commercialization. Adi’s group of experienced scientists and engineers are engaged in bringing new BAE technologies to product development, customer-centric advancements, and continuous improvement of Lonza internal systems. Adi also supports collaboration with internal R&D within the Lonza Small Molecules business unit.

Register Free: https://www.pharmtech.com/pt_w/patient-preference